Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $7.00 → $0.20 | Buy → Hold | Aegis Capital |
| 7/8/2021 | $7.00 | Buy | Aegis Capital |
| 6/28/2021 | $6.00 | Buy | Maxim Group |
Studies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice (GLP) studies will evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety requir
Analysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD. Phototoxicity testing is a part of preclinical safety assessment evaluating whether a novel pharmaceutical compound could become harmful when exposed to UV light. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive p
Product Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects Corporate and Business Development Highlights: Strengthened intellectual property portfolio with new patent issuances and allowances across EVM301 and EVM401 series Announced the withdrawal by AbbVie, Inc. of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric's issued U.S. Patent No. 12,138,27
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
S-8 - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously
Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00
Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance
ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h
Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),